Introduction:

In recent years, various occlusive devices have been developed that make it possible to avoid cardiac surgery in patients with congenital heart disease with pulmonary hyperflow.

Objective:

To describe the experience in percutaneous closure in heart disease with hyperflow.

Material and methods:

Through a descriptive, retrospective study, the medical records of patients undergoing cardiac intervention were reviewed, from 2016 to 2020.

Results:

Of 706 procedures performed in this time, 35% corresponded to various therapeutic cases. Of these, 189 corresponded to our series of operated patients with diagnoses of PDA (n = 164), ASD (n = 21) and VSD (n = 4). The clinical and demographic data were: in PDA 3.4 years (0.7-15) and 10.2 kg (6.1-46), in ASD 7.2 years (6-15) and 17.5 kg (15-38), and in VSD 7.25 years (6-9) and 20.75 kg (16-27). Regarding the size of the heart defects, the average was 4.3 mm PDA, 19.1 mm ASD and 6.75 mm VSD. The most used occluding devices were Amplatzer PDA and ASD, and Occlutech PDA. The success rate was adequate, PDA 95%, ASD 90% and VSD 75%. We report a low incidence of complications and generally minor ones such as residual shunt and hemolysis.

Conclusions:

The interventional management of the congenital heart diseases with pulmonary hyperflow is increasingly frequent with the availability of occlusive as well as the development of new centers and more training of interventional cardiologists, which has allowed better success rates and lower complication rate.

        · resumen en Español     · texto en Español     · Español ( pdf )